Syn-Coll
A synthetic signal peptide that mimics thrombospondin-1 to activate TGF-beta signaling, stimulating type I and III collagen production in dermal fibroblasts for anti-wrinkle and skin-firming effects.
What is Syn-Coll?
Syn-Coll (Palmitoyl Tripeptide-5) is a synthetic lipopeptide developed by Pentapharm (now dsm-firmenich) consisting of three amino acids — lysine-valine-lysine (Lys-Val-Lys) — conjugated to palmitic acid for enhanced skin penetration. It is classified as a signal peptide: it mimics a functional motif of thrombospondin-1 (TSP-1), an extracellular matrix glycoprotein that activates latent transforming growth factor-beta (TGF-beta). By triggering TGF-beta signaling, Syn-Coll stimulates dermal fibroblasts to increase production of type I and type III collagen, fibronectin, and other extracellular matrix proteins. It also inhibits collagen-degrading matrix metalloproteinases (MMP-1 and MMP-3), providing dual action — building new collagen while protecting existing collagen from enzymatic breakdown. Its molecular formula is C33H65N5O5 with a molecular weight of approximately 612 Da (CAS 623172-56-5).
What Syn-Coll Is Investigated For
Syn-Coll is investigated as a topical cosmetic signal peptide for wrinkle reduction and skin firming, operating through a thrombospondin-1 mimetic mechanism that activates latent TGF-β and stimulates type I and type III collagen synthesis in dermal fibroblasts. The strongest available evidence is the underlying TSP-1/TGF-β biology — one of the best-characterized pathways in extracellular matrix research — plus manufacturer-sponsored 84-day clinical testing showing roughly 12% wrinkle-depth reduction at 2.5% concentration versus 7% at 1%. The honest caveats are significant. Independent human trials on Syn-Coll specifically are largely absent, most in vivo data is Pentapharm/DSM-associated or comes from multi-ingredient formulations that make attribution difficult, and the core mechanistic claim — that the KVK tripeptide functionally mimics TSP-1's KRFK activation motif at the LAP interface — rests primarily on manufacturer assertion rather than independent structural or binding studies. Clinical effect sizes are modest (in the 7–30% wrinkle reduction range over months), head-to-head evidence of superiority over other matrikine peptides like Matrixyl is not robust, and real-world penetration to viable fibroblasts is likely the practical bottleneck rather than peptide potency at the target cell.
History & Discovery
Syn-Coll was developed by Pentapharm (now part of dsm-firmenich) in Switzerland in the early 2000s and trademarked as a synthetic biomimetic of thrombospondin-1 (TSP-1). The design rationale was rooted in matricellular biology: TSP-1 is a major in vivo activator of latent transforming growth factor-beta (TGF-β), the master cytokine driving fibroblast collagen synthesis. The activating motif within TSP-1 is the KRFK sequence in the second type 1 repeat, which displaces the latency-associated peptide (LAP) and exposes mature TGF-β to its receptors. Pentapharm's design distilled this activation chemistry into a much smaller synthetic tripeptide (Pal-Lys-Val-Lys) intended to engage the same activation mechanism while being practical to formulate as a topical cosmetic active. The palmitoyl conjugation was added to improve stratum corneum penetration, following the same lipidation strategy used for Pentapharm's matrikine peptides (Matrixyl-family Pal-KTTKS, Pal-GHK, Pal-GQPR). Marketed as Syn-Coll under the Pentapharm/DSM/dsm-firmenich umbrella, the peptide rode the early 2000s wave of 'collagen-stimulating peptide' cosmeceutical product positioning. Independent academic literature on Syn-Coll specifically remains thin — most efficacy data trace back to manufacturer-associated studies — though the underlying TSP-1/TGF-β activation biology is well grounded in the broader extracellular matrix research literature.
How It Works
Syn-Coll tricks your skin into making more collagen. It mimics a natural protein called thrombospondin-1 that activates TGF-beta, one of the most powerful signals telling fibroblasts (skin's collagen factories) to produce collagen. When Syn-Coll activates TGF-beta, fibroblasts ramp up production of type I and type III collagen — the structural proteins that keep skin firm and smooth. At the same time, Syn-Coll blocks MMP-1 and MMP-3, enzymes that break down existing collagen. The result is a two-pronged approach: more collagen production plus less collagen destruction.
Syn-Coll (Palmitoyl-Lys-Val-Lys) is a synthetic lipopeptide designed to mimic the TGF-beta-activating function of thrombospondin-1 (TSP-1). TSP-1 activates latent TGF-beta through its KRFK sequence (K412-R-F-K415) in the second type 1 repeat, which interacts with the LSKL sequence in the latency-associated peptide (LAP), displacing LAP from the mature TGF-beta domain and enabling receptor binding. Syn-Coll's KVK sequence is proposed to engage a similar activation mechanism. Once TGF-beta binds its type I/II serine-threonine kinase receptors on dermal fibroblasts, it initiates SMAD2/3-dependent transcriptional signaling, upregulating genes encoding type I collagen (COL1A1/COL1A2), type III collagen (COL3A1), fibronectin, and other ECM components. In vitro studies in human dermal fibroblasts show increased steady-state levels of type I and type III collagen mRNA following Syn-Coll treatment. Additionally, Syn-Coll downregulates expression of matrix metalloproteinases MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1), which are responsible for cleaving fibrillar collagens and activating other MMPs in the degradation cascade. The palmitoyl moiety enhances stratum corneum penetration and provides anchorage in lipid bilayers, improving bioavailability at the dermal-epidermal junction. This dual mechanism — stimulating neocollagenesis while inhibiting collagenolysis — is supported by in vitro data from the manufacturer (Pentapharm/DSM), though independent replication in peer-reviewed studies remains limited.
Evidence Snapshot
Human Clinical Evidence
Limited but promising. An 84-day manufacturer-sponsored clinical study in 45 volunteers compared 1% and 2.5% Syn-Coll creams applied twice daily against placebo. PRIMOS 3D surface topography analysis showed wrinkle reduction of 7% (1%) and 12% (2.5%), with the higher concentration demonstrating approximately 3.5-fold greater wrinkle-smoothing effect compared to placebo. A separate 4-week study in 33 female Chinese volunteers using 2.5% Syn-Coll reported 77% of subjects noticed improved skin firmness and elasticity, and 60% reported reduced pore size. A nanoliposome formulation combining Syn-Coll with Argireline and carnosine showed 25% wrinkle volume reduction and 36.6% improvement in skin elasticity after 28 days in 15 women. However, most studies are manufacturer-sponsored or use multi-ingredient formulations, making attribution to Syn-Coll alone difficult.
Animal / Preclinical
Limited direct animal data for Syn-Coll specifically. In vitro studies in human dermal fibroblasts demonstrate increased type I and type III collagen mRNA expression and protein production following TGF-beta pathway activation. MMP-1 and MMP-3 inhibition has been shown in cell culture models. The underlying TSP-1/TGF-beta mechanism is well-established from extensive animal research — TSP-1-null mice show impaired TGF-beta activation and wound healing defects similar to TGF-beta1 knockout phenotypes (PMID: 10708953).
Mechanistic Rationale
Moderate. The TSP-1-mediated activation of latent TGF-beta is one of the best-characterized mechanisms in extracellular matrix biology, with the KRFK activation sequence thoroughly documented (PMID: 10224129, 7706271). TGF-beta's role as a master regulator of collagen synthesis in dermal fibroblasts is well-established. The specific connection — that Syn-Coll's KVK sequence functionally mimics TSP-1's KRFK sequence — is plausible but relies primarily on manufacturer data rather than independent structural or binding studies.
Research Gaps & Open Questions
What the current literature has not yet settled about Syn-Coll:
- 01Independent, non-industry-funded human trials on Syn-Coll specifically — most published in vivo efficacy data is Pentapharm/DSM-associated, and rigorous independent replication at clinically relevant concentrations and durations is largely absent.
- 02Direct binding and structural confirmation that Syn-Coll's KVK sequence functionally mimics TSP-1's KRFK activation motif at the LAP interface — this is the core mechanistic claim and rests primarily on manufacturer assertion rather than independent biochemical or structural studies.
- 03Head-to-head comparisons with established collagen-stimulating cosmetic peptides (Matrixyl-family, GHK-Cu) — whether Syn-Coll produces meaningful additional or differential benefit over matrikines is not rigorously established by independent trial data.
- 04Real-world skin-penetration quantification of Pal-KVK across commercial formulations — delivery to viable fibroblasts varies by vehicle, and effective dose at the target cell is poorly characterized.
- 05Long-term (multi-year) use data — most studies run 4–12 weeks; whether chronic continuous use over years sustains benefit, attenuates, or has any unrecognized signals related to sustained TGF-β activation has not been studied.
- 06Whether stacking Syn-Coll with other matrikine peptides produces additive collagen stimulation or redundant pathway activation — multi-peptide product designs are common but synergy is more marketing claim than demonstrated clinical fact.
Forms & Administration
Syn-Coll is used exclusively as a topical cosmeceutical ingredient. It is formulated in serums, creams, eye treatments, and lotions at typical concentrations of 1-3%. The commercial product (SYN-COLL by dsm-firmenich) is supplied as a solution for incorporation into finished cosmeceutical formulations. Clinical testing used twice-daily application. It is commonly used as a standalone anti-aging active or combined with complementary peptides such as Argireline (neurotransmitter inhibitor), Matrixyl (collagen signal peptide), or carnosine (antioxidant). Topical cosmeceutical use does not require a prescription.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Cosmetic formulations typically include Syn-Coll at 1–3% of the finished product, with manufacturer clinical testing centered on 1% and 2.5% concentrations. The 2.5% level showed approximately 12% wrinkle-depth reduction at 84 days versus ~7% at 1% in PRIMOS 3D surface topography measurements — consistent with a modest dose-response within the tested range. Higher percentages on labels yield diminishing returns relative to formulation quality and vehicle.
Frequency
Applied topically once or twice daily to clean skin. Manufacturer trial protocols used twice-daily application for 28–84 days before measuring wrinkle-depth, firmness, or elasticity endpoints.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Syn-Coll acts as a chronic TGF-β-activating signal to fibroblasts; sustained application is the premise of the effect, and no cycling strategy is described in the cosmetic literature. Benefit recedes with discontinuation as the matrikine signal is withdrawn and collagen turnover continues.
Protocol Notes
The palmitoyl conjugation is the critical formulation choice that distinguishes Syn-Coll from a bare tripeptide. Palmitic acid dramatically improves partition into the lipid-rich stratum corneum, which is where a hydrophilic Lys-Val-Lys tripeptide alone would stall. Even so, only a small fraction of applied palmitoyl-KVK reaches viable epidermis and the dermal-epidermal junction in typical cosmetic formulations — the gap between in vitro fibroblast assays and in vivo human wrinkle-depth effects reflects this delivery bottleneck more than mechanism failure. In practice, Syn-Coll is frequently co-formulated with other cosmetic peptides (Matrixyl-family matrikines, Argireline and SNAP-8 for neuromuscular modulation, carnosine as antioxidant) and with established actives (retinoids, vitamin C, niacinamide). Layering with retinoids is generally compatible and is the most commonly recommended pairing for anti-aging routines. Strong acids (high-concentration vitamin C, AHA exfoliants) are best separated to different times of day to avoid destabilizing the peptide in the vehicle. Injectable Syn-Coll is not an established category — it is a topical cosmeceutical active, not an injectable peptide, and there is no published rationale or safety basis for injection.
Syn-Coll is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language.
Timeline of Effects
Onset
Surface-level smoothing and hydration effects from vehicle ingredients appear within days. Fibroblast-mediated collagen signaling needs weeks to translate into measurable structural changes; manufacturer studies typically begin reporting statistically significant wrinkle-depth or firmness improvements at 4 weeks of twice-daily application, with 77% of subjects in a 4-week study reporting noticeable firmness improvement at 2.5% concentration.
Peak Effect
Maximum measured effect in published studies is typically reported at 8–12 weeks. The 84-day Pentapharm study reported approximately 12% wrinkle-depth reduction at 2.5% concentration versus placebo. Multi-peptide nanoliposomal formulations combining Syn-Coll with Argireline and carnosine have reported larger effect sizes (25% wrinkle volume reduction, 36.6% elasticity improvement at 28 days), but multi-ingredient designs make attribution to Syn-Coll specifically difficult.
After Discontinuation
Benefits recede gradually over weeks to months as collagen turnover replaces treated tissue and the matrikine signal is withdrawn. No rebound or withdrawal pattern is described — skin returns toward its pre-treatment trajectory rather than to a worse state.
Common Questions
Who Syn-Coll Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential.
- •Known hypersensitivity to Syn-Coll or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); contact dermatitis is uncommon but reported.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy. Because TGF-β signaling is involved in tissue remodeling and wound healing, a conservative default is to minimize biologically active peptide use during this window.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-aging peptides.
- •Active or recent-history skin malignancy on the application area — TGF-β signaling is implicated in tumor microenvironment biology in complex and context-dependent ways. The systemic exposure from topical use is negligible, but localized application to areas of active or recent cutaneous malignancy should be discussed with a clinician.
- •Do not inject cosmetic Syn-Coll preparations — these are not sterile injectable products and there is no clinical basis for injection.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Syn-Coll are minimal. Systemic absorption from typical topical use is low, and the palmitoylated peptide is not expected to reach clinically relevant plasma levels or interact meaningfully with oral or injected medications. The relevant interaction space is topical layering. Syn-Coll is compatible with most cosmetic actives — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with other matrikine peptides (Matrixyl-family Pal-GHK, Pal-KTTKS, Pal-GQPR) is common and marketed as synergistic, though the peptides operate through related collagen-stimulating pathways and combination benefit beyond a single well-formulated matrikine product is not clearly established. Pairing with neuromuscular peptides (Argireline, SNAP-8, Syn-Ake) combines independent mechanisms and is a rational stacking choice. Retinoids are commonly paired with Syn-Coll and the combination is generally regarded as complementary (retinoids via retinoic acid receptor activation; Syn-Coll via TGF-β pathway activation). High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize the peptide; spacing to different times of day is sensible. Strong AHA/BHA exfoliation on the same evening as Syn-Coll can reduce peptide activity at the surface and increase irritation. Syn-Coll does not interact with anticoagulants, hormonal therapies, or systemic medications at the level of topical cosmetic exposure.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Injectable use is not established for humans
- • TGF-beta activation has complex downstream effects — topical use keeps activity localized to skin
- • Most efficacy data comes from manufacturer-sponsored studies, not independent peer-reviewed trials
- • Quality and concentration vary across cosmeceutical and research suppliers
What We Don't Know
Long-term safety of topical Syn-Coll is supported by widespread cosmeceutical use but not by formal long-term clinical trials. The Cosmetic Ingredient Review (CIR) panel has deemed palmitoyl oligopeptides safe for topical cosmetic use, but systemic effects of injectable or oral administration have not been studied. The extent to which topical TGF-beta activation translates to meaningful dermal collagen remodeling in vivo — versus surface-level improvements — remains an open question.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Palmitoyl tripeptide-5 is INCI-listed and in widespread commercial use across cosmeceutical and consumer skincare products. Not approved as a drug for wrinkles or any other medical indication — labels are limited to cosmetic appearance claims.
International
Permitted as a cosmetic ingredient across the EU (CosIng database), UK, Canada, Australia, Japan, and most major markets. Cosmetic Ingredient Review (CIR) and analogous bodies have assessed palmitoyl-oligopeptide cosmetic ingredients as safe at typical formulation levels. No jurisdictions treat it as a prescription substance.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides operate at the skin surface with negligible systemic exposure relevant to performance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Topical Syn-Coll produces collagen remodeling comparable to professional collagen-stimulating treatments.
Reality
Topical Syn-Coll is a legitimate cosmetic active that may modestly increase collagen-related signaling in the fibroblasts it actually reaches. Treatments that produce substantial collagen remodeling — fractional laser, microneedling with RF, injectable biostimulators like poly-L-lactic acid — operate at a different depth and scale. Syn-Coll complements those treatments; it does not substitute for them.
Myth
Syn-Coll is dramatically more effective than Matrixyl because it activates TGF-β directly.
Reality
Manufacturer claims of '60% greater collagen I production than palmitoyl pentapeptide' come from in vitro fibroblast culture under manufacturer-controlled conditions, not from in vivo head-to-head clinical trials measuring wrinkle-depth or firmness endpoints. In practice, both peptides produce modest in vivo effects in the 7–30% range over months, and clinically meaningful superiority of one matrikine over another is not robustly established.
Myth
Higher-concentration Syn-Coll products give proportionally better results.
Reality
Manufacturer data shows roughly 12% wrinkle reduction at 2.5% versus 7% at 1% — a real but modest dose-response. Above ~3% in finished products, additional concentration mainly increases label appeal. The bottleneck is stratum corneum penetration and delivery to viable fibroblasts, not bulk peptide concentration in the serum.
Myth
Syn-Coll can be safely injected for a stronger effect.
Reality
Cosmetic Syn-Coll preparations are not sterile injectable products, not manufactured under injectable standards, and there is no authorized injectable category. Injecting cosmetic peptide products carries documented infection risk, and the peptide's mechanism does not become injection-potent the way collagen-stimulating biostimulators (PLLA, PCL) are designed for in-office injectable use.
Myth
Because it activates a 'natural' signaling pathway, Syn-Coll has no theoretical safety concerns.
Reality
TGF-β is a powerful pleiotropic cytokine with context-dependent roles in tissue remodeling, fibrosis, immune modulation, and tumor microenvironment biology. Topical cosmetic exposure keeps activity localized to skin and is generally well-tolerated, but 'mimics a natural pathway' is not the same as 'has no theoretical safety considerations.' This is part of why injection is not an authorized use case and why pregnancy use is approached conservatively.
Published Research
9 studiesDelivery of Active Peptides by Self-Healing, Biocompatible and Supramolecular Hydrogels
Explores hydrogel delivery systems for palmitoyl tripeptide-5 and transdermal permeation.
Usage of Synthetic Peptides in Cosmetics for Sensitive Skin
Identifies palmitoyl tripeptide-5 as a signal peptide in 17% of analyzed cosmetics for sensitive skin, noting limited independent clinical evidence.
Thrombospondin-1 regulation of latent TGF-beta activation: a therapeutic target for fibrotic disease
Reviews TSP-1 as a major activator of TGF-beta1 in vivo and its role in tissue repair and fibrosis.
Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology
Foundational review of TSP-1-mediated TGF-beta activation mechanism that Syn-Coll is designed to mimic.
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta
Characterizes the KRFK activation sequence in TSP-1 and its interaction with LAP to activate latent TGF-beta.
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1
Identifies specific TSP-1 sequences responsible for TGF-beta activation, establishing the molecular basis for Syn-Coll's design.
Topical Peptide Treatments with Effective Anti-Aging Results
Comprehensive review of cosmeceutical peptides including palmitoyl tripeptide-5 as a signal peptide that stimulates collagen via TGF-beta.
Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers
Reviews Syn-Coll as a TSP-1 mimetic that upregulates TGF-beta to enhance collagen synthesis and skin elasticity.
Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy
Reviews cosmeceutical peptides including signal peptides that modulate TGF-beta for collagen stimulation.
Quick Facts
- Class
- Cosmeceutical Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 9PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.